Shufeng Xingbi Therapy Restores Immune and Microbiota Balanc
2026-06-06
Shufeng Xingbi Therapy Restores Immune and Microbiota Balance in AR Rats
Study Background and Research Question
Allergic rhinitis (AR) is a prevalent, chronic inflammatory disease characterized by symptoms such as sneezing, nasal congestion, and itching, with global prevalence rates exceeding 10%. The disease is driven by an imbalance in T helper (Th1/Th2) immune responses, leading to excessive IgE-mediated inflammation of the nasal mucosa. Current pharmacological interventions (e.g., glucocorticoids, antihistamines) can relieve symptoms but may cause systemic side effects, especially in pediatric populations. There is growing interest in how the gut microbiota influences immune homeostasis, as microbial metabolites like short-chain fatty acids (SCFAs) are implicated in modulating allergic inflammation. Traditional Chinese Medicine (TCM) approaches, such as Shufeng Xingbi Therapy (SFXBT), have been clinically applied for AR, yet their immunological and microbiome mechanisms remain incompletely defined.Key Innovation from the Reference Study
The study by Shuiping Yan and colleagues (bioRxiv preprint) provides a comprehensive preclinical analysis of SFXBT in an ovalbumin (OVA)-induced rat model of AR. Its central innovation lies in integrating immune profiling (Th1/Th2 balance), mucosal pathology, and gut microbiota composition to elucidate the therapeutic mechanism of SFXBT. Notably, the research dissects both systemic (serum IgE, IL-4) and local (nasal mucosa cytokines, transcription factors) immunological endpoints alongside advanced 16S rDNA microbiome sequencing, revealing how SFXBT orchestrates cross-talk between immune and microbial compartments.Methods and Experimental Design Insights
Thirty-two male Sprague Dawley rats were randomized into four groups: control, OVA-induced AR, antibiotic + SFXBT, and acetic acid + SFXBT. The OVA group served as the disease model, while both SFXBT groups received oral and nasal interventions post-OVA sensitization, either following gut flora depletion (antibiotic pretreatment) or mucosal irritation (acetic acid). Key experimental endpoints included:- AR behavioral scoring: Quantification of sneezing, nasal rubbing, and discharge frequency.
- Histopathology: Hematoxylin and eosin staining of nasal mucosa for inflammatory cell infiltration.
- Microbiota analysis: 16S rDNA sequencing of colonic contents to evaluate phylum/genus-level shifts.
- Immunological assays: ELISA for serum IgE, IL-4, and SCFAs; RT-qPCR and Western blot for key regulators (STAT5, STAT6, GATA3) in nasal tissue.
Core Findings and Why They Matter
Relative to the OVA group, both SFXBT-treated cohorts exhibited significant reductions in AR behavioral scores, indicating symptomatic improvement. Histological analysis confirmed reduced inflammatory infiltration and restoration of nasal mucosal integrity. At the phylum level, SFXBT increased the relative abundance of Firmicutes and decreased Bacteroidetes, while at the genus level, beneficial taxa such as Lactobacillus, Romboutsia, Allobaculum, and Dubosiella were markedly enriched. These shifts are consistent with a healthier gut ecosystem. Immunologically, SFXBT reduced serum IgE and IL-4, key mediators of Th2-driven allergic responses. The therapy also increased SCFA levels, suggesting enhanced anti-inflammatory signaling. Notably, expression of STAT5, STAT6, and GATA3—critical transcriptional drivers of Th2 polarization—was suppressed at both mRNA and protein levels in nasal mucosa. Collectively, these results support a dual mechanism for SFXBT: restoration of Th1/Th2 immune balance and beneficial reconfiguration of the intestinal microbiota, both essential for mitigating AR pathophysiology (reference).Comparison with Existing Internal Articles
Several recent internal reviews have explored molecular tools and mechanistic probes that intersect with the immune-microbiota axis in allergic and inflammatory diseases. For example, “Neomycin Sulfate: Mechanistic Leverage and Strategic Frontiers” highlights how neomycin sulfate, beyond its classical role as an aminoglycoside antibiotic, is employed in models of immune imbalance and microbiome disruption—paralleling the antibiotic pretreatment arm of the SFXBT study. This article underscores the utility of neomycin sulfate in RNA/DNA structure interaction studies and as a ryanodine receptor channel blocker, facilitating mechanistic dissection of immune and microbial pathways. Additionally, “Shufeng Xingbi Therapy Modulates Immunity and Gut Microbiota in AR Rats” provides a concise summary of the therapeutic effect observed in the referenced preclinical trial, reinforcing the translational relevance of immune and microbiome modulation. These resources collectively contextualize the reference study within a broader landscape of mechanistic and translational research tools.Limitations and Transferability
While the study delivers compelling evidence for SFXBT’s dual action on immune balance and microbiota composition, several limitations should be noted. First, the preclinical findings in OVA-induced rat models may not fully extrapolate to human AR, given interspecies differences in immune regulation and gut ecology. The mechanisms linking specific microbial taxa shifts to immune modulation remain correlative rather than causative in this design. Moreover, the influence of individual SFXBT herbal components was not dissected, leaving open questions regarding the contribution of specific phytochemicals or potential interactions with antibiotics such as neomycin sulfate in experimental settings. Nevertheless, the integration of immunological and microbiome endpoints provides a valuable framework for future translational studies, especially those employing molecular biology reagents for targeted manipulation of the microbiota or immune signaling pathways.Protocol Parameters
- OVA-induced AR modeling: Sensitize rats with OVA (intraperitoneal injections and intranasal challenges) to induce robust allergic rhinitis phenotypes.
- Antibiotic pretreatment: Administer broad-spectrum antibiotics such as neomycin sulfate prior to SFXBT to deplete gut microbiota, enabling assessment of microbiome-dependent effects.
- SFXBT administration: Combine oral (Shufeng Xingbi recipe) and nasal (Xingbi gel) delivery to achieve both systemic and local therapeutic action.
- Microbiota and immune profiling: Utilize 16S rDNA sequencing for gut flora analysis, ELISA for serum cytokines/SCFAs, and RT-qPCR/Western blot for tissue-specific gene/protein expression.